Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3045 in Healthy Subjects
NCT06883695Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SHR-3045 Group with SHR-3045 Placebo Group (2 arms). Primary endpoint: Adverse events. Started Apr 2025; status: completed.
02
Drugs
shr-3045
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06883695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06883695.